China Resources Boya Bio pharmaceutical Group Co Ltd

The company maintains a strong liquidity position, with a current ratio of 13.08, indicating a high ability to meet short-term obligations. However, the risk assessment notes that net cash is negative after subtracting total debt, suggesting potential liquidity constraints. The debt-to-equity ratio is 0.0, reflecting a conservative capital structure with no long-term debt obligations.

Profitability metrics show a return on equity of 2.19% and a return on assets of 2.04%, which are below the industry median for pharmaceutical firms. The gross profit margin is 65.37%, while the operating margin is 42.90%, both of which are in line with the sector average. The net profit margin is 36.65%, indicating strong cost control and pricing power.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The company's operating cash flow of 211.66 million CNY supports its capital expenditures of -51.67 million CNY, indicating a net cash inflow from operations.

The company's revenue growth is expected to remain stable, with no significant changes in the current fiscal year or the next. The operating cash flow is projected to remain positive, supporting continued investment in R&D and capital expenditures. The company's capital expenditures are expected to remain negative, indicating a focus on cost optimization.

The risk assessment highlights a medium liquidity risk due to the negative net cash position after debt. The dilution risk is low, with no significant dilution potential in the near term. The company has not issued new shares recently, and there are no indications of upcoming equity offerings.

Recent filings and transcripts indicate that the company is focused on expanding its product pipeline in oncology and autoimmune diseases. The company has also emphasized cost control and operational efficiency in its recent investor communications. Analysts have provided a mean price target of 28.55 CNY, with a median recommendation of 3.00, indicating a neutral outlook.

Analysts project 82.9% upside to a mean price target of 28.56 CNY, significantly above the current market price of 15.61 CNY.

The firm maintains a zero debt-to-equity ratio, placing it in the top quartile for leverage safety within its peer group.

Cash conversion efficiency of 1.29 exceeds the cohort median of 0.95, indicating superior ability to turn earnings into cash.

The four-year net income CAGR of -24.4% reflects a consistent and steep long-term decline in earnings power.

Revenue ¥2.06B, +18,7% YoY; Operating income −77,3% YoY.

• ▍Revenue ¥2.06B, +18,7% YoY
• ▍Operating income −77,3% YoY
• ▍Net income −71,6% YoY
• ▍Free cash flow −715,9% YoY
• ▍Net margin 5.5%

Revenue ¥1.73B, −34,6% YoY; Operating income +34,4% YoY.

• ▍Revenue ¥1.73B, −34,6% YoY
• ▍Operating income +34,4% YoY
• ▍Net income +67,2% YoY
• ▍Free cash flow −44,2% YoY
• ▍Net margin 22.9%

Revenue ¥2.65B, −3,9% YoY; Operating income −33,2% YoY.

• ▍Revenue ¥2.65B, −3,9% YoY
• ▍Operating income −33,2% YoY
• ▍Net income −45,1% YoY
• ▍Free cash flow −61,4% YoY
• ▍Net margin 9.0%

Revenue ¥2.76B, +4,1% YoY; Operating income +20,2% YoY.

• ▍Revenue ¥2.76B, +4,1% YoY
• ▍Operating income +20,2% YoY
• ▍Net income +25,4% YoY
• ▍Free cash flow −6,3% YoY
• ▍Net margin 15.7%

Revenue ¥2.65B; Operating income ¥442.3M.

• ▍Revenue ¥2.65B
• ▍Operating income ¥442.3M
• ▍Net margin 13.0%